Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte egress from lymph nodes through down-modulation of sphingosine 1-phosphate (S1P) receptors. We aimed to clarify the alterations in peripheral blood T cell subsets associated with MS relapse on fingolimod.Blood sa...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4412716?pdf=render |
| _version_ | 1811288872231895040 |
|---|---|
| author | Zi-Ye Song Ryo Yamasaki Yuji Kawano Shinya Sato Katsuhisa Masaki Satoshi Yoshimura Dai Matsuse Hiroyuki Murai Takuya Matsushita Jun-ichi Kira |
| author_facet | Zi-Ye Song Ryo Yamasaki Yuji Kawano Shinya Sato Katsuhisa Masaki Satoshi Yoshimura Dai Matsuse Hiroyuki Murai Takuya Matsushita Jun-ichi Kira |
| author_sort | Zi-Ye Song |
| collection | DOAJ |
| description | Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte egress from lymph nodes through down-modulation of sphingosine 1-phosphate (S1P) receptors. We aimed to clarify the alterations in peripheral blood T cell subsets associated with MS relapse on fingolimod.Blood samples successively collected from 23 relapsing-remitting MS patients before and during fingolimod therapy (0.5 mg/day) for 12 months and 18 healthy controls (HCs) were analysed for T cell subsets by flow cytometry. In MS patients, the percentages of central memory T (CCR7+CD45RO+) cells (TCM) and naïve T (CCR7+CD45RO-) cells decreased significantly, while those of effector memory T (CCR7-CD45RA-) and suppressor precursor T (CD28-) cells increased in both CD4+T and CD8+T cells from 2 weeks to 12 months during fingolimod therapy. The percentages of regulatory T (CD4+CD25highCD127low) cells in CD4+T cells and CCR7-CD45RA+T cells in CD8+T cells also increased significantly. Eight relapsed patients demonstrated greater percentages of CD4+TCM than 15 non-relapsed patients at 3 and 6 months (p=0.0051 and p=0.0088, respectively). The IL17-, IL9-, and IL4-producing CD4+T cell percentages were significantly higher at pre-treatment in MS patients compared with HCs (p<0.01 for all), while the IL17-producing CD4+T cell percentages tended to show a transient increase at 2 weeks of fingolimod therapy (pcorr=0.0834).The CD4+TCM percentages at 2 weeks to 12 months during fingolimod therapy are related to relapse. |
| first_indexed | 2024-04-13T03:45:00Z |
| format | Article |
| id | doaj.art-ba39fc9fcabd435982a67dd37289ce15 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T03:45:00Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ba39fc9fcabd435982a67dd37289ce152022-12-22T03:04:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01104e012492310.1371/journal.pone.0124923Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.Zi-Ye SongRyo YamasakiYuji KawanoShinya SatoKatsuhisa MasakiSatoshi YoshimuraDai MatsuseHiroyuki MuraiTakuya MatsushitaJun-ichi KiraFingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte egress from lymph nodes through down-modulation of sphingosine 1-phosphate (S1P) receptors. We aimed to clarify the alterations in peripheral blood T cell subsets associated with MS relapse on fingolimod.Blood samples successively collected from 23 relapsing-remitting MS patients before and during fingolimod therapy (0.5 mg/day) for 12 months and 18 healthy controls (HCs) were analysed for T cell subsets by flow cytometry. In MS patients, the percentages of central memory T (CCR7+CD45RO+) cells (TCM) and naïve T (CCR7+CD45RO-) cells decreased significantly, while those of effector memory T (CCR7-CD45RA-) and suppressor precursor T (CD28-) cells increased in both CD4+T and CD8+T cells from 2 weeks to 12 months during fingolimod therapy. The percentages of regulatory T (CD4+CD25highCD127low) cells in CD4+T cells and CCR7-CD45RA+T cells in CD8+T cells also increased significantly. Eight relapsed patients demonstrated greater percentages of CD4+TCM than 15 non-relapsed patients at 3 and 6 months (p=0.0051 and p=0.0088, respectively). The IL17-, IL9-, and IL4-producing CD4+T cell percentages were significantly higher at pre-treatment in MS patients compared with HCs (p<0.01 for all), while the IL17-producing CD4+T cell percentages tended to show a transient increase at 2 weeks of fingolimod therapy (pcorr=0.0834).The CD4+TCM percentages at 2 weeks to 12 months during fingolimod therapy are related to relapse.http://europepmc.org/articles/PMC4412716?pdf=render |
| spellingShingle | Zi-Ye Song Ryo Yamasaki Yuji Kawano Shinya Sato Katsuhisa Masaki Satoshi Yoshimura Dai Matsuse Hiroyuki Murai Takuya Matsushita Jun-ichi Kira Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. PLoS ONE |
| title | Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. |
| title_full | Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. |
| title_fullStr | Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. |
| title_full_unstemmed | Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. |
| title_short | Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. |
| title_sort | peripheral blood t cell dynamics predict relapse in multiple sclerosis patients on fingolimod |
| url | http://europepmc.org/articles/PMC4412716?pdf=render |
| work_keys_str_mv | AT ziyesong peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT ryoyamasaki peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT yujikawano peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT shinyasato peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT katsuhisamasaki peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT satoshiyoshimura peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT daimatsuse peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT hiroyukimurai peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT takuyamatsushita peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod AT junichikira peripheralbloodtcelldynamicspredictrelapseinmultiplesclerosispatientsonfingolimod |